[HTML][HTML] Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation …

D Husereau, M Drummond, S Petrou, C Carswell… - Value in health, 2013 - Elsevier
Background Economic evaluations of health interventions pose a particular challenge for
reporting because substantial information must be conveyed to allow scrutiny of study …

Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value

E Zoons, MGW Dijkgraaf, JM Dijk, IN Van Schaik… - Journal of …, 2012 - Springer
Focal dystonia is a common, invalidating neurologic condition characterized by involuntary,
sustained muscle contractions causing twisting movements and abnormal postures in one …

[HTML][HTML] A global comparison of the cost of patented cancer drugs in relation to global differences in wealth

DA Goldstein, J Clark, Y Tu, J Zhang, F Fang… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Results Cancer drug prices are highest in the United States. Cancer drugs are the least
affordable in India by a large margin. Despite lower prices than in the USA, cancer drugs are …

Extending the human papillomavirus vaccination programme to include males in high-income countries: a systematic review of the cost-effectiveness studies

MB Ben Hadj Yahia, A Jouin-Bortolotti… - Clinical drug …, 2015 - Springer
Abstract Background and Objectives Giving the human papillomavirus (HPV) vaccination to
females has been shown to be cost-effective in most countries. The epidemiological …

The availability, pricing, and affordability of essential diabetes medicines in 17 low-, middle-, and high-income countries

ZUD Babar, S Ramzan, F El-Dahiyat… - Frontiers in …, 2019 - frontiersin.org
Background: One third of the world population does not have access to essential medicines.
Diabetes require a long-term therapy, which incurs significant health care cost and thus …

Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report—Part I

JW Hay, J Smeeding, NV Carroll, M Drummond… - Value in …, 2010 - Wiley Online Library
Objectives: The assignment of prices or costs to pharmaceuticals can be crucial to results
and conclusions that are derived from pharmacoeconomic cost effectiveness analyses …

[HTML][HTML] An economic assessment model for in-center, conventional home, and more frequent home hemodialysis

P Komenda, MB Gavaghan, SS Garfield, AW Poret… - Kidney international, 2012 - Elsevier
More intensive and/or frequent hemodialysis may provide clinical benefits to patients with
end-stage renal disease; however, these dialysis treatments are more convenient to the …

Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean region

S Salmasi, KS Lee, LC Ming, CF Neoh, ME Elrggal… - BMC cancer, 2017 - Springer
Background Globally, cancer is one of the leading causes of mortality. High treatment cost,
partly owing to higher prices of anti-cancer drugs, presents a significant burden on patients …

Cost comparisons and methodological heterogeneity in cost-of-illness studies: the example of colorectal cancer

AJÓ Céilleachair, P Hanly, M Skally, C O'Neill… - Medical care, 2013 - journals.lww.com
Background: Colorectal cancer (CRC) is the third most common cancer worldwide with over
1 million new cases diagnosed each year. Advances in treatment and survival are likely to …

Economic Evaluation of a Personalized Nutrition Plan Based on Omic Sciences Versus a General Nutrition Plan in Adults with Overweight and Obesity: A Modeling …

MMJ Galekop, C Uyl-de Groot, WK Redekop - PharmacoEconomics-Open, 2024 - Springer
Background Since there is no diet that is perfect for everyone, personalized nutrition
approaches are gaining popularity to achieve goals such as the prevention of obesity …